Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.

Mokabberi R, Haftbaradaran A, Ravakhah K.

J Clin Pharm Ther. 2010 Apr;35(2):195-200. doi: 10.1111/j.1365-2710.2009.01073.x.

PMID:
20456738
2.

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.

Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023.

PMID:
18343274
3.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.

Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.

Curr Med Res Opin. 2008 Mar;24(3):895-906. doi: 10.1185/030079908X273408.

PMID:
18419876
4.

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.

Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH; Community-Acquired Pneumonia Recovery in the Elderly Study Group..

Clin Infect Dis. 2006 Jan 1;42(1):73-81. Epub 2005 Nov 22. Erratum in: Clin Infect Dis. 2006 May 1;42(9):1350.

PMID:
16323095
5.

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia.

Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R.

Arch Intern Med. 1999 Feb 8;159(3):266-70.

PMID:
9989538
6.
7.

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.

Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.

Curr Med Res Opin. 2009 Apr;25(4):859-68. doi: 10.1185/03007990902779749 .

PMID:
19231913
8.

Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.

Erard V, Lamy O, Bochud PY, Bille J, Cometta A, Calandra T.

Eur J Clin Microbiol Infect Dis. 2004 Feb;23(2):82-8. Epub 2004 Jan 15.

PMID:
14727149
9.

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.

File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N.

Curr Med Res Opin. 2004 Sep;20(9):1473-81.

PMID:
15383197
10.

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.

Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R; 308 Study Group..

Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5.

PMID:
18990531
11.

Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.

Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM.

Curr Med Res Opin. 2004 Apr;20(4):555-63. Erratum in: Curr Med Res Opin. 2004 Jun;20(6):967.

PMID:
15119993
12.

Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.

Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O.

Eur Respir J. 2004 Oct;24(4):644-8.

13.

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group..

Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519.

PMID:
18419482
14.

Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.

Clark LC, Davis CW.

Am J Health Syst Pharm. 2000 Nov 15;57 Suppl 3:S10-3.

PMID:
11098314
15.
16.

An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.

Rittenhouse BE, Stinnett AA, Dulisse B, Henke CJ, Potter L, Parasuraman B, Martens LL, Williams RR, Kojak C.

Am J Manag Care. 2000 Mar;6(3):381-9.

18.
19.

Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.

Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.

Treat Respir Med. 2004;3(5):329-36.

PMID:
15606222
20.

An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.

Lin TY, Lin SM, Chen HC, Wang CJ, Wang YM, Chang ML, Wang CH, Liu CY, Lin HC, Yu CT, Hsieh LL, Kuo HP, Huang CD.

Chang Gung Med J. 2007 Jul-Aug;30(4):321-32.

Supplemental Content

Support Center